$12.32 Million in Sales Expected for Theravance Biopharma Inc (TBPH) This Quarter

Wall Street brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to post sales of $12.32 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Theravance Biopharma’s earnings. The lowest sales estimate is $10.40 million and the highest is $13.96 million. Theravance Biopharma posted sales of $4.52 million in the same quarter last year, which would indicate a positive year over year growth rate of 172.6%. The firm is expected to announce its next quarterly earnings results on Tuesday, February 26th.

On average, analysts expect that Theravance Biopharma will report full-year sales of $57.86 million for the current year, with estimates ranging from $55.00 million to $60.00 million. For the next fiscal year, analysts forecast that the firm will report sales of $75.73 million, with estimates ranging from $56.30 million to $100.00 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. The business had revenue of $12.84 million during the quarter, compared to the consensus estimate of $10.55 million. Theravance Biopharma had a negative return on equity of 505.90% and a negative net margin of 513.41%.

A number of equities analysts have recently issued reports on TBPH shares. ValuEngine raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Friday, November 30th. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 27th. Piper Jaffray Companies reissued a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, October 23rd. Cantor Fitzgerald reissued a “buy” rating and set a $55.00 target price on shares of Theravance Biopharma in a research note on Monday, October 22nd. Finally, Leerink Swann set a $38.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, November 7th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $43.40.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its stake in Theravance Biopharma by 4.6% in the 2nd quarter. Rhumbline Advisers now owns 39,781 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 1,757 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in Theravance Biopharma by 7.2% in the 3rd quarter. Virtus ETF Advisers LLC now owns 32,226 shares of the biopharmaceutical company’s stock valued at $1,053,000 after purchasing an additional 2,171 shares in the last quarter. United Services Automobile Association purchased a new position in Theravance Biopharma in the 3rd quarter valued at approximately $210,000. Xact Kapitalforvaltning AB purchased a new position in Theravance Biopharma in the 3rd quarter valued at approximately $285,000. Finally, Man Group plc purchased a new position in Theravance Biopharma in the 3rd quarter valued at approximately $292,000. 83.93% of the stock is owned by hedge funds and other institutional investors.

Shares of TBPH stock traded up $0.10 during trading hours on Friday, reaching $27.15. 108,300 shares of the company’s stock were exchanged, compared to its average volume of 165,137. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -4.98 and a beta of 1.89. Theravance Biopharma has a 1 year low of $21.27 and a 1 year high of $35.48. The company has a current ratio of 3.26, a quick ratio of 3.08 and a debt-to-equity ratio of 6.52.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.

Recommended Story: How do candlesticks reflect price movement?

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply